BPDCN – Blastic Plasmacytoid Dendritic Cell Neoplasm: Patient Factsheet

BPDCN – Blastic Plasmacytoid Dendritic Cell Neoplasm: Patient Factsheet

This patient-facing factsheet produced by Cancer Patients Europe provides an accessible overview of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), a rare and aggressive blood cancer primarily affecting adults aged 60–70. It covers disease definition, typical presenting signs, the diagnostic pathway — including skin biopsy and CD123/CD4/CD56 marker testing — and available treatment options including chemotherapy and the FDA/EMA-approved monotherapy tagraxofusp. The factsheet highlights the high rate of misdiagnosis and the average 6.2-month delay to confirmed diagnosis, emphasising the importance of early detection.